Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?

在首次治疗后扫描中发现分化型甲状腺癌的放射性碘亲和性淋巴结是否需要重复进行 (131)I 治疗?

阅读:1

Abstract

BACKGROUND: Residual/recurrent lymph node metastase (LNM) is often found after differentiated thyroid cancer (DTC) surgery. This study aimed to investigate whether patients complicated with radioiodine-avid ((131)I+) lymph nodes from DTC on the initial posttherapy scan (PTS) need repeated (131)I therapy. METHODS: From June 2013 to August 2022, DTC patients with (131)I+ lymph nodes on the initial PTS who received at least two cycles of (131)I therapy were retrospectively enrolled. They were divided into a complete response (CR) group and an incomplete response (IR) group according to their response to the initial (131)I therapy based on the 2015 American Thyroid Association (ATA) guidelines. RESULTS: A total of 170 DTC patients with (131)I+ lymph nodes on the initial PTS were included; 42/170 (24.7%) patients were classified into the CR group and 128/170 (75.9%) were classified into the IR group according to their response to the initial (131)I therapy. None of the 42 CR patients had disease progression at the subsequent follow-up, and 37/170 (21.8%) IR patients improved after repeated therapy. Univariate analysis showed that N stage (P=0.002), stimulated thyroglobulin (sTg) level before initial (131)I therapy (P<0.001), LNM size (P<0.001), number of total residual/recurrent LNM (P=0.021), radioiodine-nonavid ((131)I-) LNM (P=0.002) and ultrasound features (P<0.001) were related to the initial treatment response. On multivariate analysis, sTg level (OR=1.186, P<0.001) and LNM size (OR=1.533, P=0.004) were independent risk factors for IR after initial (131)I therapy. The optimal sTg level and LNM size cutoff value for predicting the treatment response after initial (131)I therapy were 18.2 µg/l and 5mm. CONCLUSION: This study suggested that approximately one-quarter of patients with (131)I+ lymph nodes on initial PTS, especially those with N0 or N1a stage, lower sTg level, smaller LNM size, ≤2 residual/recurrent LNMs, negative ultrasound features and no (131)I- LNM, remain stable after one cycle of (131)I therapy and do not need repeated therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。